Non-interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Thailand)
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Edoxaban (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions
- Acronyms ETNA-AF-Thailand
- Sponsors Daiichi Sankyo Company
- 25 Sep 2017 Planned primary completion date changed from 1 Aug 2021 to 1 Sep 2021.
- 25 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Oct 2017.
- 14 Aug 2017 New trial record